Browsing by Author "Inanç, M"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
    Yildirim, HC; Mutlu, E; Chalabiyev, E; Özen, M; Keskinkiliç, M; Ön, S; Çelebi, A; Dursun, B; Acar, O; Kahraman, S; Aykan, MB; Kaman, O; Dogan, A; Erdogan, AP; Celayir, OM; Günenç, D; Güven, DC; Bayoglu, IV; Yavuzsen, T; Hacibekiroglu, I; Inanç, M; Kiliçkap, S; Yalçin, S; Aksoy, S
    Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4-6 inhibitors in a multicenter real-life cohort. Methods: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4-6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. Results: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04-25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4-6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. Conclusion: In our study, we found that CDK 4-6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4-6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer.
  • No Thumbnail Available
    Item
    Impact of rheumatoid arthritis in Turkey: a questionnaire study
    Direskeneli, H; Akkoç, N; Bes, C; Çakir, N; Çefle, A; Çobankara, V; Dalkiliç, E; Dinç, A; Ertenli, T; Gül, A; Hamuryudan, V; Inanç, M; Kalyoncu, U; Karaaslan, Y; Kasifoglu, T; Keser, G; Keskin, G; Kisacik, B; Kiraz, S; Masatlioglu, S; Onat, AM; Özbek, S; Öztürk, MA; Pamuk, ÖN; Pay, S; Pirildar, T; Sayarlioglu, M; Senel, S; Sentürk, T; Tasan, D; Terzioglu, E; Yazici, A; Yücel, E
    Objective Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study.